SCHEMBL23728240

SCHEMBL23728240

COc1ccc2c(=O)c[c]oc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.57
MAOB P27338 3/20 0.53
ALDH1A1 P00352 9/20 0.50
EPHX2 P34913 1/20 0.50
TNKS O95271 1/20 0.50
CYP19A1 P11511 1/20 0.50
HPGD P15428 5/20 0.49
HSD17B10 Q99714 3/20 0.49
CYP3A4 P08684 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
USP2 O75604 1/20 0.49
MAPK1 P28482 1/20 0.49
RECQL P46063 1/20 0.49
MAPT P10636 5/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
POLB P06746 1/20 0.49
STAT1 P42224 1/20 0.49
MEN1 O00255 1/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533148 0.75 ALDH1A1 (0.49) KDM4EMAOBALDH1A1HPGDHSD17B10
SCHEMBL208305 0.74 TNKS (0.36) MAOBTNKSHPGDCYP3A4MAPK1
7-Methoxychromone SCHEMBL31260290 0.72 KDM4E (1.00) KDM4EMAOBALDH1A1EPHX2TNKS
7-Methoxychromone SCHEMBL1854902 0.72 KDM4E (1.00) KDM4EMAOBALDH1A1EPHX2TNKS
SCHEMBL533282 0.72 CYP2A6 (0.47) KDM4EMAOBALDH1A1HPGDHSD17B10
SCHEMBL1500139 0.71 MAOB (0.67) KDM4EMAOBALDH1A1EPHX2TNKS
SCHEMBL9976083 0.71 MAOB (0.67) KDM4EMAOBALDH1A1EPHX2TNKS
SCHEMBL693879 0.70 KDM4E (0.47) KDM4EMAOBALDH1A1HPGDHSD17B10
SCHEMBL10839133 0.70 ALDH1A1 (0.47) KDM4EALDH1A1CYP19A1HPGDHSD17B10
SCHEMBL207284 0.70 LOXL2 (0.49) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB KDM4E 4637/4885MAOB 3174/4885ALDH1A1 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.